Tempus enters multi-year strategic collaboration with boehringer ingelheim to advance its cancer pipeline

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced a new strategic collaboration to advance boehringer ingelheim's growing cancer pipeline. the new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and ai to further advance therapeutic research and development. despite significant breakthroughs in the un.
TEM Ratings Summary
TEM Quant Ranking